Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.

Ana Carolina Veneziani Suku Sneha Amit M Oza

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4-directed antibody-drug conjugate. See related article by Gitto et al., p. 1567.

Keyphrases

cell surface
cancer therapy
oxidative stress
poor prognosis
bone marrow
mesenchymal stem cells
oxide nanoparticles